Em­ploy­ers cov­er­ing GLP-1s could dou­ble in 2024 as ques­tions over cov­er­age guardrails loom

Em­ploy­ers who of­fer in­sur­ance cov­er­age of the new class of obe­si­ty med­ica­tions could dou­ble next year, ac­cord­ing to a new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.